Search This Blog

Tuesday, September 1, 2026

Alumis Phase 2b lupus trial misses primary, secondary endpoints; subgroup data support Phase 3 plans

 

Alumis Phase 2b LUMUS SLE trial misses primary and secondary endpoints as IFNGS-high subgroup data support Phase 3 plans

  • LUMUS Phase 2b study tested envudeucitinib in patients with systemic lupus erythematosus across an overall population.
  • Company plans Phase 3 development based on strong IFNGS-high subgroup response in systemic lupus erythematosus.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)